Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
22 current organizations shown on this profile
Board positions
22 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Appointed Executive Vice Chairman effective May 1, 2022. Member of the Board since October 2015. Previously served as President and Chief Executive Officer from March 2016 through April 2022. Founder and Chief Executive Officer and President of Leonard-Meron Biosciences, Inc. from March 2013 until March 2016.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

CITIUS ONCOLOGY, INC.

2024-01-01 · current

Confirmed by public sourceView source

Director

Citius Pharmaceuticals, Inc.

2015-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

CITIUS ONCOLOGY, INC.

Open CITIUS ONCOLOGY, INC. profile →

Director at CITIUS ONCOLOGY, INC.

2024-01-01 → End not stated

current · source reported

Observed: 2026-09-26

CITIUS ONCOLOGY, I…CITIUS ONCOLOGY, INC.Citius Pharmaceuti…Citius Pharmaceuticals, Inc.Myron Holubiak

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingCTXR DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open sourceSource 2 · Sec FilingCTXR 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 3 · Sec FilingCTOR 10-K executive officersSupports Executive company, Executive title.Open sourceSource 4 · Sec FilingCTOR DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:myron-holubiak
Record version
public-0

Published evidence records

8 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. CTXR DEF 14A director slate

    sec filing · Source published: Feb 24, 2026 · Retrieved: May 15, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Vice Chair · Claim reviewed: May 15, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Citius Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Executive Vice Chairman · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. Open source

    sec proxy · Source published: Feb 24, 2026 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at Citius Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026

  3. CTXR 10-K executive officers

    sec filing · Source published: Dec 23, 2025 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Citius Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Executive Vice Chairman and Director · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  4. CTOR 10-K executive officers

    sec filing · Source published: Dec 23, 2025 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at CITIUS ONCOLOGY, INC. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Secretary · Claim reviewed: May 16, 2026

  5. CTOR DEF 14A director slate

    sec filing · Source published: Sep 26, 2025 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026

  6. Open source

    sec proxy · Source published: Sep 26, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at CITIUS ONCOLOGY, INC. · Claim reviewed: May 16, 2026

  7. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of CITIUS ONCOLOGY, INC. · Claim reviewed: May 16, 2026

  8. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Citius Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board membership · Source reportedServes on the board of CITIUS ONCOLOGY, INC.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Citius Pharmaceuticals, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board role · Source reportedBoard role: Vice Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · CorroboratedNo committee assignment disclosed in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at CITIUS ONCOLOGY, INC.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · CorroboratedExecutive at Citius Pharmaceuticals, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Executive Vice Chairman1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Executive Vice Chairman and Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Secretary1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources8 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1506251/000121390026019566/ea0277108-def14a_citius.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  6. https://www.sec.gov/Archives/edgar/data/1851484/000121390025092369/ea0257805-def14a_citius.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at CITIUS ONCOLOGY, INC. (NASDAQ: CTOR)

  7. https://www.sec.gov/Archives/edgar/data/1851484/000121390025092369/ea0257805-def14a_citius.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  8. https://www.sec.gov/Archives/edgar/data/1506251/000121390026019566/ea0277108-def14a_citius.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership